Progeria: Clinical Trials

7 trials for Progeria, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

5 completed, 1 enrolling by invitation, 1 unknown. 7 Phase 2, 2 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 27Completed 5, Enrolling by invitation 1, Unknown 1
Phase 12Completed 1, Enrolling by invitation 1

Follow Progeria: new trials by email Literature Review of Progeria trials Research Report on Progeria

Trials (filtered) newest first · largest first

All 7 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study to Determine Optimal Dose and Evaluate Safety, Tolerability, and Pharmacokinetics of Progerinin in Patients With Hutchinson-Gilford Progeria Syndrome (HGPS)
Progerinin, Lonafarnib - Hutchinson-Gilford Progeria Syndrome
Phase 2CompletedPRG Science & Technology Co., Ltd.102025-01-132026-10-02
Umbilical Cord Blood Transfusion in Progeria Syndrome
Umbilical Cord Blood Unit - Hutchinson-Gilford Progeria Syndrome
Phase 1 / Phase 2CompletedBundang CHA Hospital22019-03-052020-11-04
Phase I/II Trial of Everolimus in Combination With Lonafarnib in Progeria
Everolimus and lonafarnib - Progeria
Phase 1 / Phase 2Enrolling by invitationBoston Children's Hospital802015-12-012026-04-02
Study of Zoledronic Acid, Pravastatin, and Lonafarnib for Patients With Progeria
Lonafarnib, Zoledronic Acid, and Pravastatin - Progeria
Phase 2UnknownBoston Children's Hospital852009-08-012023-02-27
A Study of Zoledronic Acid, Pravastatin, and Lonafarnib for Patients With Progeria
Lonafarnib, Zoledronic Acid, Pravastatin - Progeria, Hutchinson-Gilford Syndrome
Phase 2CompletedBoston Children's Hospital52009-03-012019-06-13
Treatment of the Hutchinson-Gilford Progeria Syndrome With a Combination of Pravastatin and Zoledronic Acid
Zoledronic acid, pravastatin - Hutchinson-Gilford Progeria Syndrome
Phase 2CompletedAssistance Publique Hopitaux De Marseille152008-10-012013-07-08
Phase II Trial of Lonafarnib (a Farnesyltransferase Inhibitor) for Progeria
Lonafarnib - Progeria, Hutchinson-Gilford Syndrome
Phase 2CompletedMonica E. Kleinman292007-05-012019-06-25

Broader conditions

Congenital, Hereditary, and Neonatal Diseases and Abnormalities (7)  ·  Genetic Diseases, Inborn (7)  ·  Laminopathies (7)  ·  Metabolic Diseases (7)  ·  Metabolism, Inborn Errors (7)  ·  Nutritional and Metabolic Diseases (7)

Interventions

lonafarnib (5)  ·  Pravastatin (3)  ·  Zoledronic Acid (3)  ·  Everolimus (1)  ·  Sirolimus (1)

Sponsors

Boston Children's Hospital (3)  ·  Assistance Publique Hopitaux De Marseille (1)  ·  Bundang CHA Hospital (1)  ·  Monica E. Kleinman (1)  ·  PRG Science & Technology Co., Ltd. (1)

Countries

United States (5)  ·  France (1)  ·  South Korea (1)

Top investigators

Mark W Kieran, MD, PhD (2)  ·  Mark Kieran, MD, PhD (1)  ·  Min Young Kim, MD, PhD (1)  ·  Monica Kleinman, M.D. (1)

Results publications

PMID 24795390, PMID 27400896, PMID 36507973, PMID 36919608, PMID 22083160, PMID 22460337, PMID 22752073, PMID 23012407, PMID 23179651, PMID 23897869, PMID 24249802

NIH funding

2008 (1)